<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00388297</url>
  </required_header>
  <id_info>
    <org_study_id>HD36801-TSH</org_study_id>
    <secondary_id>U10HD021410</secondary_id>
    <secondary_id>U10HD027869</secondary_id>
    <secondary_id>U10HD027917</secondary_id>
    <secondary_id>U10HD027860</secondary_id>
    <secondary_id>U10HD027915</secondary_id>
    <secondary_id>U10HD034116</secondary_id>
    <secondary_id>U10HD034208</secondary_id>
    <secondary_id>U10HD034136</secondary_id>
    <secondary_id>U10HD040500</secondary_id>
    <secondary_id>U10HD040485</secondary_id>
    <secondary_id>U10HD040544</secondary_id>
    <secondary_id>U10HD040545</secondary_id>
    <secondary_id>U10HD040560</secondary_id>
    <secondary_id>U10HD040512</secondary_id>
    <secondary_id>U10HD036801</secondary_id>
    <secondary_id>U10HD053118</secondary_id>
    <nct_id>NCT00388297</nct_id>
  </id_info>
  <brief_title>Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy</brief_title>
  <acronym>TSH</acronym>
  <official_title>A Randomized Trial of Thyroxine Therapy for Subclinical Hypothyroidism or Hypothyroxinemia Diagnosed During Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The George Washington University Biostatistics Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The George Washington University Biostatistics Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treating women, who are diagnosed with a
      mild imbalance of thyroid hormones during pregnancy, with thyroid hormone replacement affects
      their children's intellectual development at 5 years of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Published research reports have stimulated national and international controversy regarding
      the value of maternal thyroxine therapy given to improve neurodevelopment of the fetus in
      women with variously defined hypothyroidism. These reports have led to conflicting and
      confusing recommendations as to whether or not all pregnant women in the U.S. should be
      screened for subclinical hypothyroidism or hypothyroxinemia.

      Pregnant women less than 20 weeks gestation will have a blood test to screen for subclinical
      hypothyroidism or hypothyroxinemia. If eligible for the trial, patients will receive
      levothyroxine or placebo until delivery. Blood draws will be done at monthly study visits and
      the dosage will be adjusted based on test results. The children of these patients will have
      developmental testing done annually until they are 5 years of age.

      Comparison(s): thyroxine supplementation versus placebo given during pregnancy to determine
      whether therapy is effective in improving intellectual ability at 5 years of age.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intellectual Function of Children at 5 Years of Age in Women Diagnosed With a) Subclinical Hypothyroidism or b) Hypothyroxinemia During the First Half of Pregnancy, or Death.</measure>
    <time_frame>60 months of age</time_frame>
    <description>The primary outcome was death or IQ score at 5 years of age (or at 3 years of age if the 5-year examination was missing). The full-scale IQ was assessed with the use of the Wechsler Preschool and Primary Scale of Intelligence III (WPPSI-III) at 5 years of age or the overall (general conceptual ability) score from the Differential Ability Scales-II at 3 years of age if the WPPSI-III score was not available. Results are expressed as an age-standardized score, with an expected population mean of 100 and a standard deviation of 15. Death before 3 years of age was assigned a score of 0 (lowest possible rank) and was included in the estimation of the median.
For Quotient and Composite score:
below 70 is Extremely Low, 70-79 is Borderline, 80-89 is Low Average, 90-109 is Average, 110-119 is High Average, 120-129 is Superior, 130+</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Week of Gestation at Delivery</measure>
    <time_frame>Delivery</time_frame>
    <description>Gestational age at delivery and preterm birth &lt; 37 weeks' gestation or &lt; 34 weeks' gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Preterm Delivery</measure>
    <time_frame>Delivery</time_frame>
    <description>Preterm delivery at less than 37 weeks or less than 34 weeks gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Selected Cognitive Abilities From the Subscales of the Wechsler Preschool and Primary Scale of Intelligence (WPPSI-III)</measure>
    <time_frame>60 months</time_frame>
    <description>Standardized full-scale IQ scores from the Wechsler Preschool and Primary Scale of Intelligence III (WPPSI-III) at 5 years of age. Quotient and Composite scores have a mean of 100 and a standard deviation of 15. Subtest scaled scores have a mean of 10 and a standard deviation of 3.
For Quotient and Composite score:
below 70 is Extremely Low, 70-79 is Borderline, 80-89 is Low Average, 90-109 is Average, 110-119 is High Average, 120-129 is Superior, 130+ is Very Superior.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive and Achievement Levels From the Differential Ability Scales (DAS II)</measure>
    <time_frame>36 months</time_frame>
    <description>Overall general conceptual ability score as measured by the DAS-II at 36 months of age.
GCA General Conceptual Ability Classification ≥ 130 Very high 120-129 High 110-119 Above average 90-109 Average 80-89 Below average 70-79 Low
≤ 69 Very low</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive and Achievement Levels From Two DAS-II Subtests (Recall of Digits Forward and Recognition of Pictures)</measure>
    <time_frame>48 months of age</time_frame>
    <description>Cognitive and achievement levels from two DAS-II subtests (Recall of Digits Forward and Recognition of Pictures)
GCA General Conceptual Ability Classification ≥ 130 Very high 120-129 High 110-119 Above average 90-109 Average 80-89 Below average 70-79 Low
≤ 69 Very low</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive, Motor and Language Scale Scores From the Bayley Certified Scales of Infant Development III Edition</measure>
    <time_frame>12 and 24 months of age</time_frame>
    <description>Composite scores are derived for cognitive, language, and motor development and scaled to a metric, with a mean of 100, standard deviation of 15, and range of 40 to 160. Results can also be expressed as percentile ranks relative to the standardization sample, with a mean and median of 50 and range from 1 to 99</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral Problems and Social Competencies at 36 and 60 Months of Age, as Measured by the Child Behavior Checklist (CBCL)</measure>
    <time_frame>36 and 60 months of age</time_frame>
    <description>Behavioral problems and social competencies at 36 and 60 months of age, as measured by the Child Behavior Checklist (CBCL). The CBCL is filled out by the caregiver. Each of the 100 questions indicates a behavior for which the caregiver scores as Not True (0), Sometimes True (1), or Often True (2). The scores for all the questions are then summed and evaluated against the normative data/T-scores. A Tscore of less than 60 is considered to be in the normal range. A T score of 60-63 is a borderline, and a T score of more than 63 is in the clinical range. Lower scores represent better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attention Deficit Hyperactivity Disorder (ADHD) Index Score From the Connors' Rating Scales (Parent-S) - Revised</measure>
    <time_frame>48 months of age</time_frame>
    <description>The Conners' Rating Scales-Revised were used to assess attention deficit-hyperactivity disorder (ADHD). A T score of 45 to 55 is considered to be typical or average; a T score of 44 or less is not a concern, a T score of 56 to 60 is considered to be a borderline score, and a T score of 61 or higher indicates a possible or clinically significant problem.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Placental Abruption</measure>
    <time_frame>Duration of pregnancy, delivery</time_frame>
    <description>Clinically significant placental abruption will be determined by centralized (blinded) chart review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Gestational Hypertension</measure>
    <time_frame>During pregnancy and until delivery</time_frame>
    <description>Gestational hypertension defined as patient having a diastolic ≥ 90 during pregnancy without proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Preeclampsia</measure>
    <time_frame>Duration of pregnancy, Delivery</time_frame>
    <description>Preeclampsia defined as patient having a diastolic ≥ 90 during pregnancy with at least 1 + proteinuria. Preeclampsia will also include HELLP syndrome or eclampsia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational Diabetes Mellitus</measure>
    <time_frame>During pregnancy until delivery</time_frame>
    <description>A patient is considered to have gestational diabetes if clinically diagnosed with class A1 or A2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Composite Neonatal Outcome</measure>
    <time_frame>Within 72 hours of delivery.</time_frame>
    <description>The composite neonatal outcome was defined as periventricular leukomalacia, intraventricular hemorrhage of grade III or IV, necrotizing enterocolitis (stage ≥II), severe retinopathy of prematurity (stage ≥III), the severe respiratory distress syndrome, bronchopulmonary dysplasia, neonatal death, stillbirth, or serious infectious complication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Who Experienced a Stillbirth or Miscarriage</measure>
    <time_frame>Delivery</time_frame>
    <description>Stillbirth or miscarriage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Neonatal Deaths</measure>
    <time_frame>Through 72 hours post delivery</time_frame>
    <description>Fetal and neonatal death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With Apgar Score 4 at 1 Minute and &lt; 7 at 5 Minutes</measure>
    <time_frame>1 minute and 5 minutes post delivery</time_frame>
    <description>Apgar score &lt; 4 at 1 minute and &lt; 7 at 5 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants Admitted to NICU</measure>
    <time_frame>Delivery</time_frame>
    <description>Admission to NICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infants With Birth Weight &lt; 10th Percentile (Gestational Age z Score)</measure>
    <time_frame>Delivery</time_frame>
    <description>Birth weight &lt; 10th percentile (gestational age z score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Head Circumference (Centimeters)</measure>
    <time_frame>Within 24 hours of birth</time_frame>
    <description>Neonatal head circumference measured within 24 hours of birth. This measurement is included based on a report showing that maternal treatment with thyroxine for overt hypothyroidism was associated with reduced head circumference in the newborn infant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With Respiratory Distress Syndrome</measure>
    <time_frame>Delivery and greater than or equal to 24 hours</time_frame>
    <description>Respiratory distress syndrome (RDS) will be defined based on a clinical diagnosis of RDS Type I and oxygen therapy (FiO2 ≥ 0.40) for greater than or equal to 24 hours. For infants dying before 24 hours of age, a clinical diagnosis of RDS Type I and oxygen therapy (FiO2 ≥ 0.40) are sufficient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With Retinopathy or Prematurity</measure>
    <time_frame>Through 72 hours of birth</time_frame>
    <description>This diagnosis will be reached when an ophthalmologic examination of the retina has been performed and ROP is diagnosed at Stage I (demarcation line in the retina) or greater</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With Necrotizing Enterocolitis</measure>
    <time_frame>Delivery within 2 weeks of birth</time_frame>
    <description>Necrotizing enterocolitis (NEC) is defined by the following: the unequivocal presence of intramural air on abdominal x-ray, perforation seen on abdominal x-ray, clinical evidence as suggested by erythema and induration of the abdominal wall, or intra-abdominal abscess formation, or stricture formation observed at surgery or autopsy following an episode of suspected NEC. The condition is classified based on the Bell staging system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With Bronchopulmonary Dysplasia</measure>
    <time_frame>Through 72 hours post delivery</time_frame>
    <description>Bronchopulmonary dysplasia (BPD) is defined as the need for supplemental oxygen at 36 weeks corrected age, for babies born &lt;34 weeks by project gestational age only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With Respiratory Therapy Greater Than or Equal to 1 Day</measure>
    <time_frame>72 hours post delivery</time_frame>
    <description>oxygen therapy (FiO2 ≥ 0.40) for greater than or equal to 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days in the Hospital Nursery</measure>
    <time_frame>Through hospital discharge</time_frame>
    <description>Median number of days in the hospital nursery</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1203</enrollment>
  <condition>Subclinical Hypothyroidism</condition>
  <condition>Hypothyroxinemia</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Levothyroxine for Subclinical Hypothyroidism</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 µg of Levothryoxine for participants with subclinical hypothyroidism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Levothyroxine - Subclinincal Hypothyroidism</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for Levothyroxine for participants with subclinical hypothyroidism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levothyroxine for Hypothyroxinemia - Hypothyroxinemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 µg of Levothyroxine for participants with hypothyroxinemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Levothyroxine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for Levothyroxine for participants with hypothyroxinemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine</intervention_name>
    <description>Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
    <arm_group_label>Levothyroxine for Hypothyroxinemia - Hypothyroxinemia</arm_group_label>
    <arm_group_label>Levothyroxine for Subclinical Hypothyroidism</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Levothyroxine</intervention_name>
    <arm_group_label>Placebo for Levothyroxine</arm_group_label>
    <arm_group_label>Placebo for Levothyroxine - Subclinincal Hypothyroidism</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subclinical Hypothyroidism as defined by an elevated TSH (≥ 3.00 mU/L) and a free-T4
             in the normal range (i.e. 0.86 to 1.90 ng/dL) or Hypothyroxinemia as defined by a TSH
             in the normal range (0.08 to 2.99 micrometers (mU)/L) and a low free-T4 (&lt;0.86 ng/dL)

          -  Singleton Pregnancy

          -  Gestational age at randomization between 8 weeks 0 days and 20 weeks 6 days

        Exclusion Criteria:

          1. Major fetal anomaly or demise

          2. Planned termination of the pregnancy

          3. History of thyroid cancer or current thyroid disease requiring medication

          4. Diabetes, on medication (insulin, glyburide)

          5. Collagen vascular disease (autoimmune disease), such as lupus, scleroderma and
             polymyalgia rheumatica, on medication

          6. Receiving anticoagulant therapy

          7. Depression, currently on treatment with tricyclics or selective serotonin reuptake
             inhibitors (SSRIs)

          8. Other known serious maternal medical complications including:

               1. Chronic hypertension requiring antihypertensive medication (including diuretics)

               2. Epilepsy or other seizure disorder, on medication

               3. Active or chronic liver disease (acute hepatitis, chronic active hepatitis) with
                  persistently abnormal liver enzymes

               4. Cancer (including melanoma but excluding other skin cancers)

               5. Heart disease (tachyrhythmia, class II or greater heart disease or on heart
                  medication). Mitral valve prolapse without arrhythmia is not an exclusion.

               6. Asthma, on oral corticosteroids

          9. Known illicit drug or alcohol abuse during current pregnancy

         10. Delivery at a non-network hospital

         11. Participation in another intervention study that influences maternal and fetal
             morbidity and mortality, or participation in this trial in a previous pregnancy

         12. Unwilling or unable to commit to 5 year follow-up of the infant
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Casey, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Menachem Miodovnik, MD</last_name>
    <role>Study Director</role>
    <affiliation>NICHD Project Scientist</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Magee Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - Southwest</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch - Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas-Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bsc.gwu.edu/mfmu/Projects/Projects.cgi</url>
    <description>Click here for more information about this study</description>
  </link>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 12, 2006</study_first_submitted>
  <study_first_submitted_qc>October 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2006</study_first_posted>
  <results_first_submitted>October 24, 2018</results_first_submitted>
  <results_first_submitted_qc>January 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 30, 2019</results_first_posted>
  <last_update_submitted>February 19, 2019</last_update_submitted>
  <last_update_submitted_qc>February 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Subclinical Hypothyroidism</keyword>
  <keyword>Hypothyroxinemia</keyword>
  <keyword>Thyroid</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Intellectual Development</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data will be shared after the completion of the trial and publication of the main analyses per NIH policy. When made available, requests for the dataset(s) can be sent to mfmudatasets@bsc.gwu.edu.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study enrolled women with a singleton pregnancy before 20 weeks gestation who met the criteria for either subclinical hypothyroidism or hypothyroxinemia based on serum thyrotropin and free T4 values. The study was conducted as two multicenter, randomized, placebo-controlled trials at 15 NICHD MFMU network centers.</recruitment_details>
      <pre_assignment_details>97,228 patients were screened during the recruitment period October 2006 to October 2009, Of the 800 eligible based on subclinical hypothyroidism, 677 completed the 7-day placebo adherence run-in and were randomized. Of the 632 eligible based on hypothyroxinemia, 526 completed the run-in phase and were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Levothyroxine for Subclinical Hypothyroidism</title>
          <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
        </group>
        <group group_id="P2">
          <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
          <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism group</description>
        </group>
        <group group_id="P3">
          <title>Levothyroxine for Hypothyroxinemia</title>
          <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
        </group>
        <group group_id="P4">
          <title>Placebo for Levothyroxine for Hypothyroxinemia</title>
          <description>Placebo for Levothyroxine for the Hypothyroxinemia group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="339"/>
                <participants group_id="P2" count="338"/>
                <participants group_id="P3" count="265"/>
                <participants group_id="P4" count="261"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="323"/>
                <participants group_id="P2" count="326"/>
                <participants group_id="P3" count="254"/>
                <participants group_id="P4" count="253"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Levothyroxine for Subclinical Hypothyroidism</title>
          <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
        </group>
        <group group_id="B2">
          <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
          <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
        </group>
        <group group_id="B3">
          <title>Levothyroxine for Hypothyroxinemia</title>
          <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
        </group>
        <group group_id="B4">
          <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
          <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="339"/>
            <count group_id="B2" value="338"/>
            <count group_id="B3" value="265"/>
            <count group_id="B4" value="261"/>
            <count group_id="B5" value="1203"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.7" spread="5.7"/>
                    <measurement group_id="B2" value="27.3" spread="5.7"/>
                    <measurement group_id="B3" value="27.8" spread="5.7"/>
                    <measurement group_id="B4" value="28.0" spread="5.8"/>
                    <measurement group_id="B5" value="27.7" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="339"/>
                    <measurement group_id="B2" value="338"/>
                    <measurement group_id="B3" value="265"/>
                    <measurement group_id="B4" value="261"/>
                    <measurement group_id="B5" value="1203"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="131"/>
                    <measurement group_id="B4" value="125"/>
                    <measurement group_id="B5" value="636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="69"/>
                    <measurement group_id="B5" value="364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="339"/>
                    <measurement group_id="B2" value="338"/>
                    <measurement group_id="B3" value="265"/>
                    <measurement group_id="B4" value="261"/>
                    <measurement group_id="B5" value="1203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body-mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.1" spread="6.4"/>
                    <measurement group_id="B2" value="28.2" spread="6.4"/>
                    <measurement group_id="B3" value="30.3" spread="6.4"/>
                    <measurement group_id="B4" value="30.2" spread="7.1"/>
                    <measurement group_id="B5" value="29.0" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nulliparous</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline thyrotropin (mU/liter) Median</title>
          <units>mU/liter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.5" lower_limit="4.0" upper_limit="5.5"/>
                    <measurement group_id="B2" value="4.3" lower_limit="4.0" upper_limit="5.3"/>
                    <measurement group_id="B3" value="1.5" lower_limit="1.1" upper_limit="2.1"/>
                    <measurement group_id="B4" value="1.4" lower_limit="1.0" upper_limit="2.1"/>
                    <measurement group_id="B5" value="3.4" lower_limit="1.6" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline free thyroxine (ng/dl Median</title>
          <units>ng/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.01" lower_limit=".94" upper_limit="1.09"/>
                    <measurement group_id="B2" value="1.02" lower_limit="0.96" upper_limit="1.11"/>
                    <measurement group_id="B3" value="0.83" lower_limit="0.81" upper_limit="0.84"/>
                    <measurement group_id="B4" value="0.83" lower_limit="0.81" upper_limit="0.84"/>
                    <measurement group_id="B5" value="0.90" lower_limit="0.83" upper_limit="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinary iodine (µg/liter) Median</title>
          <units>µg/liter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="199" lower_limit="106" upper_limit="340"/>
                    <measurement group_id="B2" value="196" lower_limit="114" upper_limit="331"/>
                    <measurement group_id="B3" value="185" lower_limit="108" upper_limit="341"/>
                    <measurement group_id="B4" value="191" lower_limit="118" upper_limit="325"/>
                    <measurement group_id="B5" value="194" lower_limit="111" upper_limit="334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weeks Gestation at Randomization</title>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.6" spread="3.0"/>
                    <measurement group_id="B2" value="16.7" spread="3.0"/>
                    <measurement group_id="B3" value="18.0" spread="2.8"/>
                    <measurement group_id="B4" value="17.7" spread="2.9"/>
                    <measurement group_id="B5" value="17.2" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intellectual Function of Children at 5 Years of Age in Women Diagnosed With a) Subclinical Hypothyroidism or b) Hypothyroxinemia During the First Half of Pregnancy, or Death.</title>
        <description>The primary outcome was death or IQ score at 5 years of age (or at 3 years of age if the 5-year examination was missing). The full-scale IQ was assessed with the use of the Wechsler Preschool and Primary Scale of Intelligence III (WPPSI-III) at 5 years of age or the overall (general conceptual ability) score from the Differential Ability Scales-II at 3 years of age if the WPPSI-III score was not available. Results are expressed as an age-standardized score, with an expected population mean of 100 and a standard deviation of 15. Death before 3 years of age was assigned a score of 0 (lowest possible rank) and was included in the estimation of the median.
For Quotient and Composite score:
below 70 is Extremely Low, 70-79 is Borderline, 80-89 is Low Average, 90-109 is Average, 110-119 is High Average, 120-129 is Superior, 130+</description>
        <time_frame>60 months of age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Intellectual Function of Children at 5 Years of Age in Women Diagnosed With a) Subclinical Hypothyroidism or b) Hypothyroxinemia During the First Half of Pregnancy, or Death.</title>
          <description>The primary outcome was death or IQ score at 5 years of age (or at 3 years of age if the 5-year examination was missing). The full-scale IQ was assessed with the use of the Wechsler Preschool and Primary Scale of Intelligence III (WPPSI-III) at 5 years of age or the overall (general conceptual ability) score from the Differential Ability Scales-II at 3 years of age if the WPPSI-III score was not available. Results are expressed as an age-standardized score, with an expected population mean of 100 and a standard deviation of 15. Death before 3 years of age was assigned a score of 0 (lowest possible rank) and was included in the estimation of the median.
For Quotient and Composite score:
below 70 is Extremely Low, 70-79 is Borderline, 80-89 is Low Average, 90-109 is Average, 110-119 is High Average, 120-129 is Superior, 130+</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="326"/>
                <count group_id="O3" value="254"/>
                <count group_id="O4" value="253"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="94" upper_limit="99"/>
                    <measurement group_id="O2" value="94" lower_limit="92" upper_limit="96"/>
                    <measurement group_id="O3" value="94" lower_limit="91" upper_limit="95"/>
                    <measurement group_id="O4" value="91" lower_limit="89" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.71</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Hodges-Lehmann estimate</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Hodges-Lehmann estimate</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Week of Gestation at Delivery</title>
        <description>Gestational age at delivery and preterm birth &lt; 37 weeks' gestation or &lt; 34 weeks' gestation</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Week of Gestation at Delivery</title>
          <description>Gestational age at delivery and preterm birth &lt; 37 weeks' gestation or &lt; 34 weeks' gestation</description>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="338"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" spread="2.5"/>
                    <measurement group_id="O2" value="38.9" spread="3.1"/>
                    <measurement group_id="O3" value="39.0" spread="2.4"/>
                    <measurement group_id="O4" value="38.8" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.46</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Preterm Delivery</title>
        <description>Preterm delivery at less than 37 weeks or less than 34 weeks gestation</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Preterm Delivery</title>
          <description>Preterm delivery at less than 37 weeks or less than 34 weeks gestation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="338"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Preterm birth &lt; 34 wk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Preterm birth &lt; 37 wk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for &lt; 34 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.81</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis for &lt;34 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.47</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for &lt;37 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis for &lt; 37 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Bayley-III Motor (24 months)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Bayley-II Language (24 months)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Bayley-III Cognitive (12 months)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Bayley-III Motor (12 months)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.54</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Bayley-III Language (12 months)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.92</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Bayley-III Cognitive (24 months)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Bayley-III Motor (24 months)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.20</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Bayley-II Language (24 months)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.71</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Selected Cognitive Abilities From the Subscales of the Wechsler Preschool and Primary Scale of Intelligence (WPPSI-III)</title>
        <description>Standardized full-scale IQ scores from the Wechsler Preschool and Primary Scale of Intelligence III (WPPSI-III) at 5 years of age. Quotient and Composite scores have a mean of 100 and a standard deviation of 15. Subtest scaled scores have a mean of 10 and a standard deviation of 3.
For Quotient and Composite score:
below 70 is Extremely Low, 70-79 is Borderline, 80-89 is Low Average, 90-109 is Average, 110-119 is High Average, 120-129 is Superior, 130+ is Very Superior.</description>
        <time_frame>60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Selected Cognitive Abilities From the Subscales of the Wechsler Preschool and Primary Scale of Intelligence (WPPSI-III)</title>
          <description>Standardized full-scale IQ scores from the Wechsler Preschool and Primary Scale of Intelligence III (WPPSI-III) at 5 years of age. Quotient and Composite scores have a mean of 100 and a standard deviation of 15. Subtest scaled scores have a mean of 10 and a standard deviation of 3.
For Quotient and Composite score:
below 70 is Extremely Low, 70-79 is Borderline, 80-89 is Low Average, 90-109 is Average, 110-119 is High Average, 120-129 is Superior, 130+ is Very Superior.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="314"/>
                <count group_id="O3" value="243"/>
                <count group_id="O4" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="95" upper_limit="99"/>
                    <measurement group_id="O2" value="95" lower_limit="93" upper_limit="97"/>
                    <measurement group_id="O3" value="94" lower_limit="91" upper_limit="95"/>
                    <measurement group_id="O4" value="92" lower_limit="90" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive and Achievement Levels From the Differential Ability Scales (DAS II)</title>
        <description>Overall general conceptual ability score as measured by the DAS-II at 36 months of age.
GCA General Conceptual Ability Classification ≥ 130 Very high 120-129 High 110-119 Above average 90-109 Average 80-89 Below average 70-79 Low
≤ 69 Very low</description>
        <time_frame>36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive and Achievement Levels From the Differential Ability Scales (DAS II)</title>
          <description>Overall general conceptual ability score as measured by the DAS-II at 36 months of age.
GCA General Conceptual Ability Classification ≥ 130 Very high 120-129 High 110-119 Above average 90-109 Average 80-89 Below average 70-79 Low
≤ 69 Very low</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="308"/>
                <count group_id="O3" value="244"/>
                <count group_id="O4" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="88" upper_limit="93"/>
                    <measurement group_id="O2" value="90" lower_limit="87" upper_limit="93"/>
                    <measurement group_id="O3" value="90" lower_limit="87" upper_limit="92"/>
                    <measurement group_id="O4" value="89" lower_limit="87" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.64</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive and Achievement Levels From Two DAS-II Subtests (Recall of Digits Forward and Recognition of Pictures)</title>
        <description>Cognitive and achievement levels from two DAS-II subtests (Recall of Digits Forward and Recognition of Pictures)
GCA General Conceptual Ability Classification ≥ 130 Very high 120-129 High 110-119 Above average 90-109 Average 80-89 Below average 70-79 Low
≤ 69 Very low</description>
        <time_frame>48 months of age</time_frame>
        <population>For all outcomes except the primary outcome, the potential follow-up cohort consisted of 335 children in the levothyroxine group and 329 in the placebo group for the mothers with subclinical hypothyroidism and for the hypothyroxinemia group - 260 children in the levothyroxine group and 255 children in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive and Achievement Levels From Two DAS-II Subtests (Recall of Digits Forward and Recognition of Pictures)</title>
          <description>Cognitive and achievement levels from two DAS-II subtests (Recall of Digits Forward and Recognition of Pictures)
GCA General Conceptual Ability Classification ≥ 130 Very high 120-129 High 110-119 Above average 90-109 Average 80-89 Below average 70-79 Low
≤ 69 Very low</description>
          <population>For all outcomes except the primary outcome, the potential follow-up cohort consisted of 335 children in the levothyroxine group and 329 in the placebo group for the mothers with subclinical hypothyroidism and for the hypothyroxinemia group - 260 children in the levothyroxine group and 255 children in the placebo group.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="329"/>
                <count group_id="O3" value="260"/>
                <count group_id="O4" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Median Recall of Digits Forward Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="298"/>
                    <count group_id="O2" value="299"/>
                    <count group_id="O3" value="236"/>
                    <count group_id="O4" value="224"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="76" upper_limit="91"/>
                    <measurement group_id="O2" value="84" lower_limit="76" upper_limit="91"/>
                    <measurement group_id="O3" value="91" lower_limit="84" upper_limit="99"/>
                    <measurement group_id="O4" value="74" lower_limit="74" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median Recognition of Pictures Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="298"/>
                    <count group_id="O2" value="302"/>
                    <count group_id="O3" value="234"/>
                    <count group_id="O4" value="226"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="74" upper_limit="80"/>
                    <measurement group_id="O2" value="74" lower_limit="74" upper_limit="80"/>
                    <measurement group_id="O3" value="84" lower_limit="84" upper_limit="91"/>
                    <measurement group_id="O4" value="74" lower_limit="74" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for recall of digits forward</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.60</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5</ci_lower_limit>
            <ci_upper_limit>7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis for recall of digits forward</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for Recognition of Pictures</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.52</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis for Recognition of Pictures</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.91</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive, Motor and Language Scale Scores From the Bayley Certified Scales of Infant Development III Edition</title>
        <description>Composite scores are derived for cognitive, language, and motor development and scaled to a metric, with a mean of 100, standard deviation of 15, and range of 40 to 160. Results can also be expressed as percentile ranks relative to the standardization sample, with a mean and median of 50 and range from 1 to 99</description>
        <time_frame>12 and 24 months of age</time_frame>
        <population>For all outcomes except the primary outcome the potential follow-up cohort in the subclinical hypothyroidism groups consisted of 335 children in the levothyroxine group and 329 in the placebo group, and for the hypothyroxinema groups: 254 children in the levothryoxine group and 253 children in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive, Motor and Language Scale Scores From the Bayley Certified Scales of Infant Development III Edition</title>
          <description>Composite scores are derived for cognitive, language, and motor development and scaled to a metric, with a mean of 100, standard deviation of 15, and range of 40 to 160. Results can also be expressed as percentile ranks relative to the standardization sample, with a mean and median of 50 and range from 1 to 99</description>
          <population>For all outcomes except the primary outcome the potential follow-up cohort in the subclinical hypothyroidism groups consisted of 335 children in the levothyroxine group and 329 in the placebo group, and for the hypothyroxinema groups: 254 children in the levothryoxine group and 253 children in the placebo group.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="326"/>
                <count group_id="O3" value="254"/>
                <count group_id="O4" value="253"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Median 12 mo cognitive score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="311"/>
                    <count group_id="O2" value="315"/>
                    <count group_id="O3" value="247"/>
                    <count group_id="O4" value="238"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="100" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median 12 mo motor score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="312"/>
                    <count group_id="O2" value="314"/>
                    <count group_id="O3" value="246"/>
                    <count group_id="O4" value="236"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="97" upper_limit="97"/>
                    <measurement group_id="O2" value="97" lower_limit="97" upper_limit="97"/>
                    <measurement group_id="O3" value="97" lower_limit="94" upper_limit="97"/>
                    <measurement group_id="O4" value="97" lower_limit="94" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median 12 mo language score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="309"/>
                    <count group_id="O2" value="312"/>
                    <count group_id="O3" value="246"/>
                    <count group_id="O4" value="237"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="94" upper_limit="97"/>
                    <measurement group_id="O2" value="94" lower_limit="94" upper_limit="97"/>
                    <measurement group_id="O3" value="94" lower_limit="91" upper_limit="94"/>
                    <measurement group_id="O4" value="94" lower_limit="91" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median 24 mo cognitive score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="308"/>
                    <count group_id="O2" value="302"/>
                    <count group_id="O3" value="235"/>
                    <count group_id="O4" value="235"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="90" upper_limit="90"/>
                    <measurement group_id="O2" value="90" lower_limit="90" upper_limit="90"/>
                    <measurement group_id="O3" value="90" lower_limit="85" upper_limit="90"/>
                    <measurement group_id="O4" value="90" lower_limit="85" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median 24 mo motor score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="304"/>
                    <count group_id="O2" value="300"/>
                    <count group_id="O3" value="233"/>
                    <count group_id="O4" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="97" upper_limit="97"/>
                    <measurement group_id="O2" value="97" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O3" value="97" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O4" value="97" lower_limit="94" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median 24 mo language score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="300"/>
                    <count group_id="O2" value="296"/>
                    <count group_id="O3" value="232"/>
                    <count group_id="O4" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="89" upper_limit="91"/>
                    <measurement group_id="O2" value="91" lower_limit="89" upper_limit="94"/>
                    <measurement group_id="O3" value="89" lower_limit="89" upper_limit="94"/>
                    <measurement group_id="O4" value="89" lower_limit="89" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Bayley II Cognitive (12 months)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.63</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Bayley II Motor (12 mo)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Bayley-III Language (12 months)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Bayley-III Cognitive (24 months)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.59</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Behavioral Problems and Social Competencies at 36 and 60 Months of Age, as Measured by the Child Behavior Checklist (CBCL)</title>
        <description>Behavioral problems and social competencies at 36 and 60 months of age, as measured by the Child Behavior Checklist (CBCL). The CBCL is filled out by the caregiver. Each of the 100 questions indicates a behavior for which the caregiver scores as Not True (0), Sometimes True (1), or Often True (2). The scores for all the questions are then summed and evaluated against the normative data/T-scores. A Tscore of less than 60 is considered to be in the normal range. A T score of 60-63 is a borderline, and a T score of more than 63 is in the clinical range. Lower scores represent better outcomes.</description>
        <time_frame>36 and 60 months of age</time_frame>
        <population>The potential follow-up cohort consisted of 335 children in the levothyroxine group and 329 in the placebo group for subclinical hypothyroidism and for hypothyroxinemia - 260 children in the levothyroxine group and 255 in the placebo group. A Child Behavior Checklist T score of less than 60 is considered to be in the normal range.</population>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Behavioral Problems and Social Competencies at 36 and 60 Months of Age, as Measured by the Child Behavior Checklist (CBCL)</title>
          <description>Behavioral problems and social competencies at 36 and 60 months of age, as measured by the Child Behavior Checklist (CBCL). The CBCL is filled out by the caregiver. Each of the 100 questions indicates a behavior for which the caregiver scores as Not True (0), Sometimes True (1), or Often True (2). The scores for all the questions are then summed and evaluated against the normative data/T-scores. A Tscore of less than 60 is considered to be in the normal range. A T score of 60-63 is a borderline, and a T score of more than 63 is in the clinical range. Lower scores represent better outcomes.</description>
          <population>The potential follow-up cohort consisted of 335 children in the levothyroxine group and 329 in the placebo group for subclinical hypothyroidism and for hypothyroxinemia - 260 children in the levothyroxine group and 255 in the placebo group. A Child Behavior Checklist T score of less than 60 is considered to be in the normal range.</population>
          <units>T-score</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="314"/>
                <count group_id="O3" value="260"/>
                <count group_id="O4" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CBCL T score at 36 mo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="306"/>
                    <count group_id="O2" value="309"/>
                    <count group_id="O3" value="244"/>
                    <count group_id="O4" value="237"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="45" upper_limit="48"/>
                    <measurement group_id="O2" value="46" lower_limit="45" upper_limit="48"/>
                    <measurement group_id="O3" value="48" lower_limit="46" upper_limit="50"/>
                    <measurement group_id="O4" value="48" lower_limit="45" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CBCL T score at 60 mo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="314"/>
                    <count group_id="O2" value="313"/>
                    <count group_id="O3" value="244"/>
                    <count group_id="O4" value="243"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="43" upper_limit="46"/>
                    <measurement group_id="O2" value="44" lower_limit="42" upper_limit="46"/>
                    <measurement group_id="O3" value="45" lower_limit="43" upper_limit="46"/>
                    <measurement group_id="O4" value="43" lower_limit="42" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CBCL at 36 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CBCL at 60 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.96</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>CBCL at 36 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>CBCL at 60 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Attention Deficit Hyperactivity Disorder (ADHD) Index Score From the Connors' Rating Scales (Parent-S) - Revised</title>
        <description>The Conners' Rating Scales-Revised were used to assess attention deficit-hyperactivity disorder (ADHD). A T score of 45 to 55 is considered to be typical or average; a T score of 44 or less is not a concern, a T score of 56 to 60 is considered to be a borderline score, and a T score of 61 or higher indicates a possible or clinically significant problem.</description>
        <time_frame>48 months of age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Attention Deficit Hyperactivity Disorder (ADHD) Index Score From the Connors' Rating Scales (Parent-S) - Revised</title>
          <description>The Conners' Rating Scales-Revised were used to assess attention deficit-hyperactivity disorder (ADHD). A T score of 45 to 55 is considered to be typical or average; a T score of 44 or less is not a concern, a T score of 56 to 60 is considered to be a borderline score, and a T score of 61 or higher indicates a possible or clinically significant problem.</description>
          <units>T-score</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="303"/>
                <count group_id="O3" value="238"/>
                <count group_id="O4" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="47" upper_limit="49"/>
                    <measurement group_id="O2" value="49" lower_limit="47" upper_limit="51"/>
                    <measurement group_id="O3" value="50" lower_limit="49" upper_limit="51"/>
                    <measurement group_id="O4" value="49" lower_limit="48" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.98</p_value>
            <method>Chi-squared</method>
            <param_type>Hodges–Lehmann</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Placental Abruption</title>
        <description>Clinically significant placental abruption will be determined by centralized (blinded) chart review</description>
        <time_frame>Duration of pregnancy, delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Placental Abruption</title>
          <description>Clinically significant placental abruption will be determined by centralized (blinded) chart review</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="338"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Gestational Hypertension</title>
        <description>Gestational hypertension defined as patient having a diastolic ≥ 90 during pregnancy without proteinuria</description>
        <time_frame>During pregnancy and until delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Gestational Hypertension</title>
          <description>Gestational hypertension defined as patient having a diastolic ≥ 90 during pregnancy without proteinuria</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="338"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.51</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Preeclampsia</title>
        <description>Preeclampsia defined as patient having a diastolic ≥ 90 during pregnancy with at least 1 + proteinuria. Preeclampsia will also include HELLP syndrome or eclampsia.</description>
        <time_frame>Duration of pregnancy, Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Preeclampsia</title>
          <description>Preeclampsia defined as patient having a diastolic ≥ 90 during pregnancy with at least 1 + proteinuria. Preeclampsia will also include HELLP syndrome or eclampsia.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="338"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.64</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gestational Diabetes Mellitus</title>
        <description>A patient is considered to have gestational diabetes if clinically diagnosed with class A1 or A2</description>
        <time_frame>During pregnancy until delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Gestational Diabetes Mellitus</title>
          <description>A patient is considered to have gestational diabetes if clinically diagnosed with class A1 or A2</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="338"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Composite Neonatal Outcome</title>
        <description>The composite neonatal outcome was defined as periventricular leukomalacia, intraventricular hemorrhage of grade III or IV, necrotizing enterocolitis (stage ≥II), severe retinopathy of prematurity (stage ≥III), the severe respiratory distress syndrome, bronchopulmonary dysplasia, neonatal death, stillbirth, or serious infectious complication.</description>
        <time_frame>Within 72 hours of delivery.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Composite Neonatal Outcome</title>
          <description>The composite neonatal outcome was defined as periventricular leukomalacia, intraventricular hemorrhage of grade III or IV, necrotizing enterocolitis (stage ≥II), severe retinopathy of prematurity (stage ≥III), the severe respiratory distress syndrome, bronchopulmonary dysplasia, neonatal death, stillbirth, or serious infectious complication.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="338"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Who Experienced a Stillbirth or Miscarriage</title>
        <description>Stillbirth or miscarriage.</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Experienced a Stillbirth or Miscarriage</title>
          <description>Stillbirth or miscarriage.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="338"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Neonatal Deaths</title>
        <description>Fetal and neonatal death</description>
        <time_frame>Through 72 hours post delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neonatal Deaths</title>
          <description>Fetal and neonatal death</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="338"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.50</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With Apgar Score 4 at 1 Minute and &lt; 7 at 5 Minutes</title>
        <description>Apgar score &lt; 4 at 1 minute and &lt; 7 at 5 minutes</description>
        <time_frame>1 minute and 5 minutes post delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Apgar Score 4 at 1 Minute and &lt; 7 at 5 Minutes</title>
          <description>Apgar score &lt; 4 at 1 minute and &lt; 7 at 5 minutes</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="338"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Apgar &lt; 4 at 1 minute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apgar &lt; 7 at 5 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Apgar at 1 min &lt; 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Apgar &gt; 4 at 1 minute</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Apgar &lt; 7 at 5 minutes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Apgar &lt; 7 at 5 minutes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.45</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants Admitted to NICU</title>
        <description>Admission to NICU</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants Admitted to NICU</title>
          <description>Admission to NICU</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="338"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infants With Birth Weight &lt; 10th Percentile (Gestational Age z Score)</title>
        <description>Birth weight &lt; 10th percentile (gestational age z score)</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Infants With Birth Weight &lt; 10th Percentile (Gestational Age z Score)</title>
          <description>Birth weight &lt; 10th percentile (gestational age z score)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="338"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.45</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.68</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Head Circumference (Centimeters)</title>
        <description>Neonatal head circumference measured within 24 hours of birth. This measurement is included based on a report showing that maternal treatment with thyroxine for overt hypothyroidism was associated with reduced head circumference in the newborn infant</description>
        <time_frame>Within 24 hours of birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Head Circumference (Centimeters)</title>
          <description>Neonatal head circumference measured within 24 hours of birth. This measurement is included based on a report showing that maternal treatment with thyroxine for overt hypothyroidism was associated with reduced head circumference in the newborn infant</description>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="338"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9" spread="1.8"/>
                    <measurement group_id="O2" value="33.9" spread="1.7"/>
                    <measurement group_id="O3" value="33.9" spread="1.8"/>
                    <measurement group_id="O4" value="34.2" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.46</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With Respiratory Distress Syndrome</title>
        <description>Respiratory distress syndrome (RDS) will be defined based on a clinical diagnosis of RDS Type I and oxygen therapy (FiO2 ≥ 0.40) for greater than or equal to 24 hours. For infants dying before 24 hours of age, a clinical diagnosis of RDS Type I and oxygen therapy (FiO2 ≥ 0.40) are sufficient.</description>
        <time_frame>Delivery and greater than or equal to 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Respiratory Distress Syndrome</title>
          <description>Respiratory distress syndrome (RDS) will be defined based on a clinical diagnosis of RDS Type I and oxygen therapy (FiO2 ≥ 0.40) for greater than or equal to 24 hours. For infants dying before 24 hours of age, a clinical diagnosis of RDS Type I and oxygen therapy (FiO2 ≥ 0.40) are sufficient.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="338"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.45</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.75</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With Retinopathy or Prematurity</title>
        <description>This diagnosis will be reached when an ophthalmologic examination of the retina has been performed and ROP is diagnosed at Stage I (demarcation line in the retina) or greater</description>
        <time_frame>Through 72 hours of birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Retinopathy or Prematurity</title>
          <description>This diagnosis will be reached when an ophthalmologic examination of the retina has been performed and ROP is diagnosed at Stage I (demarcation line in the retina) or greater</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="338"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With Necrotizing Enterocolitis</title>
        <description>Necrotizing enterocolitis (NEC) is defined by the following: the unequivocal presence of intramural air on abdominal x-ray, perforation seen on abdominal x-ray, clinical evidence as suggested by erythema and induration of the abdominal wall, or intra-abdominal abscess formation, or stricture formation observed at surgery or autopsy following an episode of suspected NEC. The condition is classified based on the Bell staging system</description>
        <time_frame>Delivery within 2 weeks of birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Necrotizing Enterocolitis</title>
          <description>Necrotizing enterocolitis (NEC) is defined by the following: the unequivocal presence of intramural air on abdominal x-ray, perforation seen on abdominal x-ray, clinical evidence as suggested by erythema and induration of the abdominal wall, or intra-abdominal abscess formation, or stricture formation observed at surgery or autopsy following an episode of suspected NEC. The condition is classified based on the Bell staging system</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="338"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.50</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With Bronchopulmonary Dysplasia</title>
        <description>Bronchopulmonary dysplasia (BPD) is defined as the need for supplemental oxygen at 36 weeks corrected age, for babies born &lt;34 weeks by project gestational age only</description>
        <time_frame>Through 72 hours post delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Bronchopulmonary Dysplasia</title>
          <description>Bronchopulmonary dysplasia (BPD) is defined as the need for supplemental oxygen at 36 weeks corrected age, for babies born &lt;34 weeks by project gestational age only</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="338"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.50</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.49</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With Respiratory Therapy Greater Than or Equal to 1 Day</title>
        <description>oxygen therapy (FiO2 ≥ 0.40) for greater than or equal to 24 hours</description>
        <time_frame>72 hours post delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Respiratory Therapy Greater Than or Equal to 1 Day</title>
          <description>oxygen therapy (FiO2 ≥ 0.40) for greater than or equal to 24 hours</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="338"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.85</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days in the Hospital Nursery</title>
        <description>Median number of days in the hospital nursery</description>
        <time_frame>Through hospital discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine for Subclinical Hypothyroidism</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Levothyroxine - Subclinical Hypothyroidism</title>
            <description>Placebo for Levothyroxine for the Subclinical Hypothyroidism</description>
          </group>
          <group group_id="O3">
            <title>Levothyroxine for Hypothyroxinemia</title>
            <description>Levothyroxine
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
          </group>
          <group group_id="O4">
            <title>Placebo for Levothyroxine - Hypothyroxinemia</title>
            <description>Placebo for Levothyroxine for the Hypothyroxinemia</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days in the Hospital Nursery</title>
          <description>Median number of days in the hospital nursery</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="338"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="2" upper_limit="2"/>
                    <measurement group_id="O2" value="2" lower_limit="2" upper_limit="2"/>
                    <measurement group_id="O3" value="2" lower_limit="2" upper_limit="2"/>
                    <measurement group_id="O4" value="2" lower_limit="2" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.39</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data on adverse events was collected for each participant beginning with enrollment through the final 5-year follow-up with the mother and child.</time_frame>
      <desc>The at-risk population for non-serious adverse events (side effects) was based on patients who had been seen for a least one study visit where side effect information was assessed, so the at-risk population for side effects varies from the total number of patients randomized and assessed for serious adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Levothyroxine for Subclinical Hypothyroidism</title>
          <description>100 µg of Levothryoxine for participants with subclinical hypothyroidism
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
        </group>
        <group group_id="E2">
          <title>Placebo for Levothyroxine - Subclinincal Hypothyroidism</title>
          <description>Placebo for Levothyroxine for participants with subclinical hypothyroidism
Placebo for Levothyroxine</description>
        </group>
        <group group_id="E3">
          <title>Levothyroxine for Hypothyroxinemia - Hypothyroxinemia</title>
          <description>50 µg of Levothyroxine for participants with hypothyroxinemia
Levothyroxine: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.</description>
        </group>
        <group group_id="E4">
          <title>Placebo for Levothyroxine</title>
          <description>Placebo for Levothyroxine for participants with hypothyroxinemia
Placebo for Levothyroxine</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="339"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Maternal atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Neonatal Severe Hearing Loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hashimoto's thryoiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Maternal death</sub_title>
                <description>Maternal death at 2 years postpartum</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Chest/abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Irregular fetal heart rate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>IUGR, non-reassuring</sub_title>
                <description>Non-reassuring Intrauterine Growth Restriction</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Abnormal Doppler</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
              <event>
                <sub_title>Neonatal Hypoxic-Ischemic Encephalopathy</sub_title>
                <description>Hypoxic-Ischemic Encephalopathy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Autism Spectrum Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="261"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting/Nausea</sub_title>
                <description>Participant reported side effect</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="261"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nervousness</sub_title>
                <description>Participant reported side effect</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Participant reported side effect</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="261"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <description>Participant reported side effect</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="261"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Other side effects</sub_title>
                <description>Participant reported side effects including allergic reaction.</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="261"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>shortness of breath</sub_title>
                <description>Participant reported side effect</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elizabeth Thom, Ph.D.</name_or_title>
      <organization>The George Washington University Biostatistics Center</organization>
      <phone>301-881-9260</phone>
      <email>e_thom@bsc.gwu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

